Skip to content
S8965Senate2023-2024 SessionSame asA6799

Teach Drug Side Effect Screening

Official title

“Establishes a drug-induced movement disorder screening education program”

Sponsor Gustavo RiveraSD-33Affects Health
Status
Senate Floor Calendar
Impact
5/10
Moderate
Outcome
Companion signed

Bill progress

Signed via A6799

What's happening

This bill requires New York's health department to create an educational program for screening and treating drug-induced movement disorders.

Why it matters

  1. Expands awareness and early detection. By requiring educational materials and outreach about recognizing drug-induced movement disorders, the bill aims to help healthcare providers identify symptoms earlier, which can lead to faster intervention and potentially better patient outcomes.

  2. Promotes up-to-date, coordinated care. The program mandates development of best practices and materials in alignment with guidelines from the American Psychiatric Association and other professional societies, ensuring that providers have access to current, evidence-based information for both in-person and telehealth services.

  3. Addresses stigma in mental health treatment. The bill specifically includes education and outreach to reduce stigma for individuals experiencing these movement disorders as a side effect of mental health treatment, which can improve patient well-being and encourage individuals to seek help without fear of judgment.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Teach Drug Side Effect Screening

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Gustavo Rivera

Senator · Senate District 33

Chair, Health

No co-sponsors yet.

History

  1. Substituted by A6799B
  2. Advanced to third reading
  3. 2nd report cal.
  4. 1st report cal.838
  5. Print number 8965a
  6. Amend and recommit to health
  7. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A6799Assembly

Train Doctors on Drug Disorders

Signed by Governor · Sponsor Amy Paulin

Impact 5 · ModerateSigned into law

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8965--A

IN SENATE

April 3, 2024

Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the public health law, in relation to establishing a drug-induced movement disorder screening education program

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 1 of section 207 of the public health law is amended by adding a new paragraph (h) to read as follows:

(h) The department shall develop and conduct a program concerning drug-induced movement disorders. Such program shall include but not be limited to, (i) educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders; and (ii) the development and dissemination of educational materials for healthcare providers regarding treatment for drug-induced movement disorders, including for services provided via telehealth. Such educational materials disseminated to healthcare providers shall be developed and disseminated in coordination with relevant healthcare provider groups and shall include best practices for the treatment and screening of movement disorders informed by the American Psychiatric Association and other professional society practice guidelines. Such program shall also include education and outreach on the elimination of stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.

§ 2. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD10964-04-4

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to establishing a drug-induced movement disorder screening education program

PURPOSE OR GENERAL IDEA OF BILL::

The purpose of this legislation is to provide educational information about the importance of screening for and recognizing symptoms of drug- induced movement disorders; develop guidance for best practices for the treatment and screening of drug-induced movement disorders, including via telehealth; and the elimination of bias and reduction of stigma for people living with drug-induced movement disorders related to the treat- ment of mental health conditions.

Read the full memo (754 words)

SUMMARY OF PROVISIONS::

Section 1 includes the legislative intent.

Section 2 requires the New York State Department of Health to establish a drug-induced movement disorder screening and awareness program within the department under the health care and wellness education and outreach program. The program would promote education and awareness of drug-in- duced movement disorders and screening of these disorders, develop best practices forthe treatment and screening of drug-induced movement disor- ders, including via telehealth, and seek to eliminate bias and reduce stigma for people living with drug-induced movement disorders.

Section 3 of this bill provides an effective date.

JUSTIFICATION::

Patients receiving treatment with medications for their mental health conditions may be at risk of developing a drug-induced movement disor- der. Drug-induced movement disorders, as discussed in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), are of "frequent importance" when mental disorders and other medical conditions are managed with antipsychotic medications. These involuntary movement disorders are caused by medications that help control dopamine, such as first- and second-generation antipsychotics commonly prescribed to treat people living with mental illnesses, including schizophrenia, bipolar disorder, and major depression. Some drug-induced movement disorders, such as tardive dyskinesia, are persistent, irreversible, and potentially disabling neurological condi- tions characterized by uncontrollable repetitive movements of the face, torso, or other parts of the body. While untreated involuntary movements can be stigmatizing and debilitating, the rates of undiagnosed patients living with drug-induced movement disorders remains high.

Awareness of and periodic screenings for such movement disorders are fundamental to the proper identification, diagnosis, and timely treat- ment of drug-induced movement disorders. Recent updates to the American Psychiatric Association's guidelines reflect the importance of screening in people at risk of developing drug-induced movement disorders, but health care and mental health providers, patients, and the public may be unaware of these standards. Under this bill, the Department of Health (DOH), through the health care and wellness education and outreach program, will provide educational information to educate providers and the public on the importance of screening and recognizing symptoms of drug-induced movement disorders; develop best practices for treating and screening drug-induced movement disorders, including for the use of telehealth; and to provide education and outreach on the elimination of stigma associated with drug-induced involuntary movements. As part of this program, the DOH should inventory existing drug-induced movement disorder resources available, develop and maintain educational materials and guidance for providers and the public, and help develop training for public safety officials to recog- nize drug-induced movement disorders.

Public education and information about drug-induced movement disorders will help health professionals, public safety officials, and the commu- nity better understand these disorders, including what causes these types of involuntary movements and their prevalence. This can help reduce stigma by clarifying that some abnormal movements that may be mistaken as a public safety concern are actually uncontrollable physical symptoms of conditions caused by medication used to treat mental illness.

In addition, services provided via telehealth to patients at risk of developing drug-induced movement disorders, such as those treated with antipsychotic medications, should align with existing standards of care. This includes ensuring that at-risk patients are periodically screened and assessed for developing drug-induced movement disorders. The needs of patients living with or at risk of developing drug-induced movement disorders encompass both mental and physical health care, and therefore may require additional considerations when determining the clinical appropriateness of telehealth.

PRIOR LEGISLATIVE HISTORY::

New bill.

FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS::

Minimal as this program will be included in the already existing Depart- ment of Health healthcare and wellness education and outreach program.

EFFECTIVE DATE::

This bill shall take effect on the 90th day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.